Predictive Life Insurance Underwriting Platform

Traditional life insurance underwriting is a serial process that takes 4-6 weeks on average: the applicant completes a lengthy application (often 40+ pages for term life), a paramedical exam is scheduled and conducted (blood draw, urine sample, vitals), the carrier orders an Attending Physician Statement from the applicant's physician (which takes 2-4 weeks to receive and is often incomplete), MIB data is retrieved, MVR records are pulled, and a human underwriter reviews the entire file to assign a risk classification (preferred plus, preferred, standard plus, standard, or substandard with table rating). The elapsed time causes 30-40% of applicants to abandon the process before a policy is issued—the insurance industry's most significant source of lost revenue.

The data that underwriters ultimately rely upon has shifted dramatically. Prescription drug history has proven to be a more powerful predictor of mortality risk than many traditional underwriting factors: an Rx profile revealing statin therapy, metformin, and an ACE inhibitor tells an experienced underwriter as much about cardiovascular risk as a full APS from a cardiologist. Electronic health records now contain structured diagnosis codes (ICD-10), lab results, vital signs, and medication lists that, in aggregate, provide a clinical picture equivalent to the APS—but available electronically in seconds rather than weeks by mail. The challenge is building a system that can ingest these heterogeneous data sources, normalize them into a consistent risk feature set, and produce a mortality risk score that is actuarially sound, regulatorily compliant, and explainable to both underwriters and state insurance departments.

Regulatory constraints add complexity. State insurance departments require that underwriting models be actuarially justified, not unfairly discriminatory (per NAIC Unfair Trade Practices Model Act), and auditable. The use of non-traditional data sources (consumer behavioral data, credit attributes) is subject to increasing scrutiny under NAIC model bulletins on algorithmic bias. Any accelerated underwriting program must demonstrate that its mortality outcomes are equivalent to or better than the traditional underwriting process it replaces, typically requiring a multi-year retrospective study or a concurrent shadow-underwriting validation.

The platform operates as a decision engine that sits between the carrier's application intake system (typically an ACORD XML or API-based e-application) and the policy administration system. Upon application submission, the engine simultaneously orders data from multiple sources: MIB coded data (checking for prior applications with adverse medical history), prescription drug history from Milliman IntelliScript or ExamOne/Quest Rx, MVR from LexisNexis, electronic health records via consumer-authorized FHIR API access (Epic MyChart, Cerner Health, CommonWell Health Alliance), identity verification and fraud screening, and credit-based insurance scores where permitted by state regulation.

The data normalization layer maps heterogeneous inputs to a standardized risk feature vector: ICD-10 diagnosis codes are grouped into actuarially meaningful condition categories (cardiovascular, oncologic, metabolic, neurological, respiratory, psychiatric), Rx fills are mapped to therapeutic drug classes using First Databank or Medi-Span classification and further to implied medical conditions (e.g., metformin implies diabetes, levothyroxine implies hypothyroidism), lab values are standardized to common units and compared against clinical reference ranges, and BMI is calculated from available height/weight data. The feature vector feeds a gradient boosting model (XGBoost or LightGBM) trained on the carrier's historical underwriting decisions and validated against actual mortality experience over a 10+ year observation period.

The model produces a mortality risk score calibrated to the carrier's risk classification tiers. Applicants with clear risk profiles (no adverse findings across all data sources, risk score within preferred or standard thresholds) are routed to straight-through processing for instant decision. Applicants with moderate complexity (some adverse findings but within guidelines) receive an AI-recommended classification with supporting evidence and are reviewed by an underwriter with decision support. Applicants with complex risk profiles (multiple serious conditions, conflicting data sources, or model uncertainty exceeding a configurable threshold) follow the traditional full-underwriting path with APS ordering. SHAP (SHapley Additive exPlanations) values provide per-feature contribution scores for every decision, enabling underwriters and regulators to understand exactly which factors drove each risk assessment.

The Rx data pipeline ingests prescription drug history in the Milliman IntelliScript response format or ExamOne RxCheck XML. Each fill record includes NDC (National Drug Code), fill date, days supply, prescriber NPI, and dispensing pharmacy. The NDC is mapped to the First Databank Enhanced Therapeutic Classification (ETC) system, which hierarchically groups drugs into therapeutic categories (e.g., NDC 00002-4210-01 → ETC 28:08.08 → 'Antidiabetic Agents, Biguanides' → implied condition: Type 2 Diabetes). Multiple fills of the same drug class within a lookback window (default 24 months) are classified as ongoing therapy versus trial or discontinued. The Rx-implied condition set is cross-referenced against the applicant's self-reported medical history on the application; discrepancies (applicant denies diabetes but has 18 months of continuous metformin fills) generate a misrepresentation flag that routes the case to human review with the specific discrepancy highlighted.

The mortality model uses LightGBM with a Cox proportional hazards objective function, trained on a dataset of 2M+ historical underwriting decisions paired with policy-level mortality outcomes over a 12-year observation period. The feature space includes 340+ variables: Rx-implied conditions (78 features), ICD-10 condition categories from EHR data (42 features), lab value standardized z-scores (28 features), MIB code categories (34 features), MVR violation counts by severity (12 features), applicant demographics (age, gender, BMI, smoking status, occupation class), and financial features (face amount, coverage ratio to income). Model performance is evaluated on discrimination (C-statistic > 0.85 on holdout), calibration (Hosmer-Lemeshow goodness-of-fit across decile risk groups), and stability (PSI < 0.10 on monthly production data versus training distribution). The model is retrained quarterly on the expanding dataset and subject to champion/challenger validation before production deployment.

Regulatory compliance uses a model governance framework aligned with NAIC Principles on Artificial Intelligence and SR 11-7 (OCC Supervisory Guidance on Model Risk Management). Every model version is documented in a model risk management inventory with: development methodology, training data summary statistics (without PII), performance metrics on validation and out-of-time samples, fairness analysis across protected classes (race proxy via BISG methodology, gender, age), and limitations documentation. State filing packages include the model's SHAP summary plots showing global feature importance, adverse action reason code logic for declined applications (per FCRA requirements where credit data is used), and the actuarial memorandum demonstrating that the accelerated underwriting program's expected mortality is within 5% of the traditional underwriting program's mortality for equivalent risk classes.